We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VistaGen

News List

VistaGen Reports Positive New Data from AV-101, Probenecid Study americanpharmaceuticalreview
September 07, 2020
VistaGen Therapeutics announced positive new data from the Company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. Probenecid has extensive data supporting its safe oral delivery and ability to ...
VistaGen, Baylor Announce Successful Results of AV-101 for Suicidal Ideation in Vets americanpharmaceuticalreview
December 20, 2019
VistaGen Therapeutics and Baylor College of Medicine announced successful results from a first-step, Phase 1b clinical study with healthy U.S. military Veterans ...
FDA Grants VistaGen Fast Track Designation for Social Anxiety Disorder Treatment americanpharmaceuticalreview
December 16, 2019
VistaGen Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for development of the Company's PH94B neuroactive nasal spray for ...